EMC3 regulates trafficking and pulmonary toxicity of the SFTPCI73T mutation associated with interstitial lung disease
Journal Article
·
· Journal of Clinical Investigation
- Fudan Univ., Shanghai (China); Cincinnati Children's Hospital Medical Center, OH (United State)
- Fudan Univ., Shanghai (China)
- Cincinnati Children's Hospital Medical Center, OH (United State)
- Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
- Boston Univ., MA (United States)
- Univ. of North Carolina, Chapel Hill, NC (United States)
The most common mutation in surfactant protein C gene (SFTPC), SFTPCI73T, causes interstitial lung disease with few therapeutic options. We previously demonstrated that EMC3, an important component of the multiprotein endoplasmic reticulum membrane complex (EMC), is required for surfactant homeostasis in alveolar type 2 epithelial (AT2) cells at birth. In the present study, we investigated the role of EMC3 in the control of SFTPCI73T metabolism and its associated alveolar dysfunction. Using a knock-in mouse model phenocopying the I73T mutation, we demonstrated that conditional deletion of Emc3 in AT2 cells rescued alveolar remodeling/simplification defects in neonatal and adult mice. Proteomic analysis revealed that Emc3 depletion reversed the disruption of vesicle trafficking pathways and rescued the mitochondrial dysfunction associated with I73T mutation. Affinity mass spectrometry analysis identified potential EMC3 interacting proteins in lung AT2 cells, including Valosin Containing Protein (VCP) and its interactors. Treatment of SftpcI73T knock-in mice and SFTPCI73T expressing iAT2 cells derived from SFTPCI73T patient-specific iPSCs with the specific VCP inhibitor CB5083 restored alveolar structure and SFTPCI73T trafficking respectively. Taken together, the present work identifies the EMC complex and VCP in the metabolism of the disease-associated SFTPCI73T mutant, providing novel therapeutical targets for SFTPCI73T-associated interstitial lung disease.
- Research Organization:
- Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
- Sponsoring Organization:
- USDOE
- Grant/Contract Number:
- AC05-76RL01830
- OSTI ID:
- 2483343
- Report Number(s):
- PNNL-SA--184548
- Journal Information:
- Journal of Clinical Investigation, Journal Name: Journal of Clinical Investigation Journal Issue: 23 Vol. 134; ISSN 1558-8238
- Publisher:
- American Society for Clinical InvestigationCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Alveolar injury and regeneration following deletion of ABCA3
EMC3 coordinates surfactant protein and lipid homeostasis required for respiration
The heterozygous R155C VCP mutation: Toxic in humans! Harmless in mice?
Journal Article
·
Wed Dec 20 23:00:00 EST 2017
· JCI Insight
·
OSTI ID:1558264
EMC3 coordinates surfactant protein and lipid homeostasis required for respiration
Journal Article
·
Thu Nov 30 23:00:00 EST 2017
· Journal of Clinical Investigation
·
OSTI ID:1542065
The heterozygous R155C VCP mutation: Toxic in humans! Harmless in mice?
Journal Article
·
Sat Sep 15 00:00:00 EDT 2018
· Biochemical and Biophysical Research Communications
·
OSTI ID:23103610